Hemopure advisory committee
FDA's Blood Products Advisory Committee will meet Dec. 14 to review Biopure's experimental blood product Hemopure [hemoglobin glutamer-250(bovine)] for out-of-hospital treatment of hermorrhagic shock, including the Navy's proposed RESUS clinical trial of the oxygen therapeutic. A closed-door meeting of the panel to discuss Hemopure was scheduled last July but was cancelled due to concerns about the need for more public input (1"The Pink Sheet" Sept. 11, 2006, p. 24). The meeting will be held from 8 a.m. to 6 p.m. at the Crown Plaza in Silver Spring, MD...
You may also be interested in...
FDA is questioning whether protocols for emergency research conducted without individual informed consent should be subjected to more public input
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.